Prognostic factors for patients with invasive ductal carcinoma of the breast who received neoadjuvant chemotherapy

e11617 Background: Neoadjuvant chemotherapy (NAC) for patients with invasive ductal carcinoma (IDC) of the breast is performed as a standard therapy in many hospitals for improving outcomes of IDC patients. The purpose of this study is to identify important prognostic clinicopathological factors for 115 IDC patients who operated in our hospital (1997 to 2002) followed by NAC. Methods: The multivariate analyses with an assessment of pathological effect of NAC, grading system for lymph vessel tumor emboli (LVTE), and histological factors of tumors in lymph nodes in addition to well-known prognostic clinicopathological factors were performed in IDC patients with nodal metastasis and in those of pTNM stage III as well as IDC patients as a whole. Results: Multivariate analyses demonstrated that grading system for LVTE was a significant prognostic factor for IDC patients in the both group. Severe tumor stroma in nodal metastatic tumors significantly increased the HRs of tumor recurrence of IDC patients in the both group. Number of mitotic figures in nodal metastatic tumors significantly increased the HRs of tumor death in IDC patients with nodal metastasis. Tumor necrosis in primary-invasive-tumors was a significant factor for tumor recurrence of patients in the both. Conclusions: The study clearly demonstrated that grading system for LVTE, and characteristics of nodal metastatic tumors as well as the presence of tumor necrosis in primary-invasive tumors are very important prognostic factors for IDC patients who received NAC. Since we already reported a prognostic significance of the factors in IDC patients who did not receive NAC in previous studies, we concluded that the factors are also very important for IDC patients who received NAC to accurately assess their outcome. No significant financial relationships to disclose.

Download Full-text

Impact of Microvascular Invasion and Tumor Necrosis on the Prognosis of Korean Patients with pT1b Renal Cell Carcinoma

Urologia Internationalis ◽

10.1159/000366138 ◽

2014 ◽

Vol 95 (1) ◽

pp. 65-71 ◽

Cited By ~ 2

Author(s):

Se Yun Kwon ◽

Jun Nyung Lee ◽

Bum Soo Kim ◽

Young Hwii Ko ◽

Phil Hyun Song ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Prognostic Factors ◽

Renal Cell ◽

Tumor Necrosis ◽

Multivariate Analyses ◽

Microvascular Invasion ◽

Recurrence Free Survival ◽

Cancer Specific Survival ◽

Free Survival

Objectives: To evaluate prognostic factors in pT1b renal cell carcinoma (RCC) patients for which no specific studies have been conducted on. Methods: The data of 270 patients diagnosed with pT1bN0M0 RCC at 2 institutions between January 1998 and June 2010 were retrospectively analyzed. Univariate and multivariate analyses using Cox proportional hazard models were used to identify pathologic and clinical factors that influenced prognosis. Five-year recurrence-free survival and cancer-specific survival were analyzed using the Kaplan-Meier method. Results: The median follow-up period was 55.5 months, and the mean patient age was 55.2 years (range: 26-80). There were 12 cancer-related deaths, and tumor recurrence was noted in 22 patients between 8 and 120 months after surgery. Sites of metastases included the lung in 13 patients, bone in 5 patients, and other sites in 4 patients. Five-year recurrence-free survival and cancer-specific survival rates were 91.2 and 93.5%, respectively. Multivariate analyses revealed that the presence of microvascular invasion and tumor necrosis independently predicted prognosis. Conclusions: Microvascular invasion and tumor necrosis were found to be independent prognostic factors in pT1b RCC. This result will help urologists to provide patients with more accurate prognoses, and patients with confirmed microvascular invasion and tumor necrosis will require closer follow-up.

Download Full-text

Circulating tumour cell enumeration does not correlate with Miller–Payne grade in a cohort of breast cancer patients undergoing neoadjuvant chemotherapy

Breast Cancer Research and Treatment ◽

10.1007/s10549-020-05658-7 ◽

2020 ◽

Vol 181 (3) ◽

pp. 571-580 ◽

Cited By ~ 1

Author(s):

Sharon A. O’Toole ◽

Cathy Spillane ◽

Yanmei Huang ◽

Marie C. Fitzgerald ◽

Brendan Ffrench ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Cancer Patients ◽

Ductal Carcinoma ◽

Lobular Carcinoma ◽

Complete Response ◽

Pathological Response ◽

Grading System ◽

Breast Cancer Patients ◽

Pre Treatment

Abstract Purpose The association between pathological complete response (pCR) in patients receiving neoadjuvant chemotherapy (NAC) for breast cancer and Circulating Tumour Cells (CTCs) is not clear. The aim of this study was to assess whether CTC enumeration could be used to predict pathological response to NAC in breast cancer as measured by the Miller–Payne grading system. Methods Twenty-six patients were recruited, and blood samples were taken pre- and post-NAC. CTCs were isolated using the ScreenCell device and stained using a modified Giemsa stain. CTCs were enumerated by 2 pathologists and classified as single CTCs, doublets, clusters/microemboli and correlated with the pathological response as measured by the Miller–Payne grading system. χ2 or ANOVA was performed in SPSS 24.0 statistics software for associations. Results 89% of patients had invasive ductal carcinoma (IDC) and 11% invasive lobular carcinoma (ILC). At baseline 85% of patients had CTCs present, median 7 (0–161) CTCs per 3 ml of whole blood. Post-chemotherapy, 58% had an increase in CTCs. This did not correlate with the Miller–Payne grade of response. No significant association was identified between the number of CTCs and clinical characteristics; however, we did observe a correlation between pre-treatment CTC counts and body mass index, p < 0.05. Conclusions Patients with a complete response to NAC still had CTCs present, suggesting enumeration is not sufficient to aid surgery stratification. Additional characterisation and larger studies are needed to further characterise CTCs isolated pre- and post-chemotherapy. Long-term follow-up of these patients will determine the significance of CTCs in NAC breast cancer patients.

Download Full-text

Completely Resected N0 Non-Small Cell Lung Cancer: Prognostic Factors Affecting Long-Term Survival

ISRN Surgery ◽

10.1155/2013/175304 ◽

2013 ◽

Vol 2013 ◽

pp. 1-7 ◽

Cited By ~ 1

Author(s):

Apichat Tantraworasin ◽

Somcharoen Saeteng ◽

Nirush Lertprasertsuke ◽

Nuttapon Arayawudhikule ◽

Choosak Kasemsarn ◽

...

Keyword(s):

Prognostic Factors ◽

Brain Metastasis ◽

Tumor Recurrence ◽

Tumor Necrosis ◽

Early Stage ◽

Adrenal Metastases ◽

Term Survival ◽

Long Term Survival ◽

Factors Affecting

Background. Although early stage non-small cell lung cancer (NSCLC) has an excellent outcome and correlated with good long-term survival, up to 15 percent of patients still relapse postoperatively and die. This study is conducted to identify prognostic factors that may affect the long-term survival in completely resected N0 NSCLC. Methods. Medical records of 124 patients with completely resected N0 NSCLC were retrospectively reviewed. Prognostic factors affecting long-term survival were analyzed by the Kaplan-Meier method and Cox proportional hazards analysis. Results. Overall five-year survival rate was 48 percent. Multivariable analysis revealed stage of disease, tumor necrosis, tumor recurrence, brain metastasis, adrenal metastases, and skin metastases as significant prognostic factors affecting long-term survival. The hazard ratio (HR) of tumor necrosis, tumor recurrence, brain metastasis, adrenal metastases, and skin metastases was 2.0, 2.3, 7.6, 4.1, and 8.3, respectively, and all P values were less than 0.001. Conclusions. Our study shows stage of disease, tumor necrosis, tumor recurrence, brain metastasis, adrenal metastasis, and skin metastasis as the independent prognostic factors of long-term survival in pathological N0 NSCLC. Early stage NSCLC patients without nodal involvement or presented with tumor necrosis should benefit from adjuvant chemotherapy, and sites of metastasis could predict the long-term survival as described.

Download Full-text

Role of photodynamic therapy using talaporfin sodium and a semiconductor laser in patients with newly diagnosed glioblastoma

Journal of Neurosurgery ◽

10.3171/2018.7.jns18422 ◽

2019 ◽

Vol 131 (5) ◽

pp. 1361-1368 ◽

Cited By ~ 18

Author(s):

Masayuki Nitta ◽

Yoshihiro Muragaki ◽

Takashi Maruyama ◽

Hiroshi Iseki ◽

Takashi Komori ◽

...

Keyword(s):

Photodynamic Therapy ◽

Prognostic Factors ◽

Local Recurrence ◽

Semiconductor Laser ◽

Tumor Recurrence ◽

Multivariate Analyses ◽

Control Group ◽

Newly Diagnosed ◽

Talaporfin Sodium ◽

Newly Diagnosed Glioblastoma

OBJECTIVEIn this study on the effectiveness and safety of photodynamic therapy (PDT) using talaporfin sodium and a semiconductor laser, the long-term follow-up results of 11 patients with glioblastoma enrolled in the authors’ previous phase II clinical trial (March 2009–2012) and the clinical results of 19 consecutive patients with newly diagnosed glioblastoma prospectively enrolled in a postmarket surveillance (March 2014–December 2016) were analyzed and compared with those of 164 patients treated without PDT during the same period.METHODSThe main outcome measures were the median overall survival (OS) and progression-free survival (PFS) times. Moreover, the adverse events and radiological changes after PDT, as well as the patterns of recurrence, were analyzed and compared between the groups. Kaplan-Meier curves were created to assess the differences in OS and PFS between the groups. Univariate and multivariate analyses were performed to identify the prognostic factors, including PDT, among patients with newly diagnosed glioblastoma.RESULTSThe median PFS times of the PDT and control groups were 19.6 and 9.0 months, with 6-month PFS rates of 86.3% and 64.9%, respectively (p = 0.016). The median OS times were 27.4 and 22.1 months, with 1-year OS rates of 95.7% and 72.5%, respectively (p = 0.0327). Multivariate analyses found PDT, preoperative Karnofsky Performance Scale score, and IDH mutation to be significant independent prognostic factors for both OS and PFS. Eighteen of 30 patients in the PDT group experienced tumor recurrence, including local recurrence, distant recurrence, and dissemination in 10, 3, and 4 patients, respectively. Conversely, 141 of 164 patients in the control group experienced tumor recurrence, including 101 cases of local recurrence. The rate of local recurrence tended to be lower in the PDT group (p = 0.06).CONCLUSIONSThe results of the present study suggest that PDT with talaporfin sodium and a semiconductor laser provides excellent local control, with few adverse effects even in cases of multiple laser irradiations, as well as potential survival benefits for patients with newly diagnosed glioblastoma.

Download Full-text

Correlation between Prognostic Factors and the Histopathological Response to Neoadjuvant Chemotherapy in Osteosarcoma: A Retrospective Study

International Journal of Surgical Oncology ◽

10.1155/2021/8843325 ◽

2021 ◽

Vol 2021 ◽

pp. 1-10

Author(s):

Yogi Prabowo ◽

Iwan Setiawan ◽

Achmad Fauzi Kamal ◽

Evelina Kodrat ◽

Muhammad Luqman Labib Zufar

Keyword(s):

Prognostic Factors ◽

Neoadjuvant Chemotherapy ◽

Tumor Size ◽

Scoring System ◽

Poor Responder ◽

Grading System ◽

Symptom Duration ◽

Histopathological Response ◽

Prognostic Features ◽

Response To Neoadjuvant Chemotherapy

Background.Multimodality treatment, incorporating neoadjuvant chemotherapy and adjuvant chemotherapy, is the standard management plan for osteosarcoma that increases the overall survival (OS) rate. However, data regarding prognostic factors affecting the histopathological response following neoadjuvant chemotherapy is limited. Patients and Methods. We retrospectively reviewed patients diagnosed with osteosarcoma in our center between 2008 and 2018. We classified patient characteristics according to gender, age, tumor size, site and stage at diagnosis, site of metastasis, type of surgery, necrosis rate based on the Huvos grading system, and the number of neoadjuvant chemotherapy cycles. We divided response to neoadjuvant chemotherapy into poor responder for patients with Huvos grades 1 and 2 and good responder for patients with Huvos grades 3 and 4. We also documented patients’ survival and follow-up information. Results. We reviewed 64 patients within 5–65 years of age, dominated by men (62.5%). The distal femur (53.1%) was the most common site of osteosarcoma. Fifteen (23.4%) patients had a good response while 49 (76.6%) patients were poor responders to neoadjuvant chemotherapy based on the Huvos grading system. Based on multivariate analysis, gender ( p = 0.012), age ( p = 0.029), symptom duration ( p = 0.004), and tumor enlargement after neoadjuvant chemotherapy ( p < 0.001) were significantly associated with histopathological response. A scoring system was proposed integrating these significant variables (age > 20 years = 1 point, female gender = 1 point, symptom duration > 12 weeks = 1 point, and increased tumor size after neoadjuvant chemotherapy = 2 points). This scoring system divides patients into two groups with a total score of more than two predicting a poor responder to neoadjuvant chemotherapy. Conclusions. Age, gender, symptoms duration, and tumor size after neoadjuvant chemotherapy are the prognostic features that affect the histopathological response to neoadjuvant chemotherapy in patients with osteosarcoma.

Download Full-text

0061 Prognostic factors for patients with invasive ductal carcinoma of the breast who received neoadjuvant chemotherapy

The Breast ◽

10.1016/s0960-9776(09)70106-7 ◽

2009 ◽

Vol 18 ◽

pp. S33

Author(s):

N. Tamura

Keyword(s):

Prognostic Factors ◽

Neoadjuvant Chemotherapy ◽

Invasive Ductal Carcinoma ◽

Ductal Carcinoma ◽

Carcinoma Of The Breast

Download Full-text

Tumour-stroma ratio is associated with Miller-Payne grading system and pathological response to neoadjuvant chemotherapy in HER2-negative breast cancer

European Journal of Surgical Oncology ◽

10.1016/j.ejso.2020.11.194 ◽

2021 ◽

Vol 47 (2) ◽

pp. e18-e19

Author(s):

Sophie Hagenaars ◽

Stefanie de Groot ◽

Danielle Cohen ◽

Tim Dekker ◽

Marjolijn Duijm-de Carpentier ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Pathological Response ◽

Grading System ◽

Tumour Stroma ◽

Response To Neoadjuvant Chemotherapy

Download Full-text

Prognostic Factors for Wilms Tumor Recurrence: A Review of the Literature

Cancers ◽

10.3390/cancers13133142 ◽

2021 ◽

Vol 13 (13) ◽

pp. 3142

Author(s):

Alissa Groenendijk ◽

Filippo Spreafico ◽

Ronald R. de Krijger ◽

Jarno Drost ◽

Jesper Brok ◽

...

Keyword(s):

Prognostic Factors ◽

Tumor Recurrence ◽

Wilms Tumor ◽

Clinicopathological Characteristics ◽

Copy Number Variations ◽

First Line ◽

Prognostic Variables ◽

Treatment Regimens ◽

International Collaborations ◽

Patients Experience

In high-income countries, the overall survival of children with Wilms tumors (WT) is ~90%. However, overall, 15% of patients experience tumor recurrence. The adverse prognostic factors currently used for risk stratification (advanced stage, high risk histology, and combined loss of heterozygosity at 1p and 16q in chemotherapy-naïve WTs) are present in only one third of these cases, and the significance of these factors is prone to change with advancing knowledge and improved treatment regimens. Therefore, we present a comprehensive, updated overview of the published prognostic variables for WT recurrence, ranging from patient-, tumor- and treatment-related characteristics to geographic and socioeconomic factors. Improved first-line treatment regimens based on clinicopathological characteristics and advancing knowledge on copy number variations unveil the importance of further investigating the significance of biological markers for WT recurrence in international collaborations.

Download Full-text